Overview

Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli in Patients With Alagille Syndrome in the European Union (LEAP-EU)

Status:
RECRUITING

Trial end date:
2030-12-22

Target enrollment:

Participant gender:

Summary

The key objectives of this low-intervention clinical study are to evaluate tolerability, long-term safety and long-term efficacy for patients with Alagille syndrome (ALGS) who are prescribed Livmarli.

Phase:

PHASE4

Details

Lead Sponsor:

Mirum Pharmaceuticals, Inc.

Treatments:

maralixibat